Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) announced on Wednesday that China's National Medical Products Administration (NMPA) has approved PADCEV (enfortumab vedotin) in combination with KEYTRUDA (pembrolizumab) for the treatment of locally advanced or metastatic urothelial cancer.
This approval was based on the Phase 3 EV-302 trial, which demonstrated significant improvements in overall survival and progression-free survival compared to platinum-based chemotherapy.
The treatment combination offers a new therapeutic option for patients with advanced bladder cancer in China. Bladder cancer is a significant public health concern in the country, with more than 92,000 new cases diagnosed in 2022.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA